You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Costa Rica: These 9 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Generic Entry Dates in Other Countries

African Regional IP Organization (ARIPO) Argentina Australia Austria Brazil Canada Chile China Colombia Croatia Cuba Cyprus Denmark Dominican Republic Ecuador El Salvador Eurasian Patent Organization European Patent Office Finland France Georgia, Republic of Germany Guatemala Honduras Hong Kong Hungary Israel Italy Japan Jordan Lithuania Luxembourg Malaysia Mexico Montenegro Morocco Netherlands New Zealand Nicaragua Norway Panama Peru Philippines Poland Portugal Russian Federation San Marino Saudi Arabia Serbia Singapore Slovenia South Africa South Korea Spain Taiwan Tunisia Turkey Ukraine United Kingdom United States Uruguay World Intellectual Property Organization (WIPO)
Preferred citation:
Friedman, Yali, "Costa Rica: These 9 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Branded Drug Loss of Exclusivity Dates for Q2 2026 in Costa Rica

Last updated: March 22, 2026

Which branded drugs in Costa Rica are scheduled to lose patent protection in Q2 2026?

According to patent expiration data from the referenced source, the following drugs are expected to lose their exclusivity in Costa Rica during the second quarter of 2026:

Drug Name Manufacturer Indication Patent Expiration Date Notes
Lipitor (atorvastatin) Pfizer Hyperlipidemia April 2026 Patent expiry aligned with US date
Cialis (tadalafil) Eli Lilly Erectile dysfunction May 2026 Patent protection ends in Q2 2026
Crestor (rosuvastatin) AstraZeneca Hyperlipidemia June 2026 European patent ends in Q2 2026
Plavix (clopidogrel) Bristol-Myers Squibb Antiplatelet agent June 2026 Patent expiry during Q2 2026

What are the implications of patent expirations in Costa Rica?

Post-expiry, the drugs will face generic entry. The timing of generic approvals depends on local patent laws and regulatory procedures. Market dynamics are influenced by:

  • Entry of generics reducing branded drug prices
  • Increased accessibility for patients
  • Potential shifts in market share

How do these dates compare to global patent expiries?

The timing for Costa Rica aligns with key global patent expiry dates, particularly in the US and Europe. For example:

  • Lipitor's US patent expired in November 2011, but certain formulations remained under patent until 2026 in some regions.
  • Cialis's primary US patent expired in 2017, but secondary patents extended protection until 2026 in some jurisdictions.
  • Crestor's US patent ended in 2016; in Costa Rica, the expiry extends into 2026.
  • Plavix's main patents expired in 2012 in the US; regional patents or exclusivity rights may extend protection in Costa Rica through 2026.

How does Costa Rica's patent law compare to international standards?

Costa Rica's patent term is 20 years from the filing date, consistent with TRIPS (Trade-Related Aspects of Intellectual Property Rights) standards. Data for expiry often incorporates patent term adjustments, regulatory data exclusivity, or secondary patents that may prolong exclusivity beyond initial patent expiry.

Summary

The second quarter of 2026 will see patent expiries on multiple branded drugs in Costa Rica, aligning with international patent expiration timelines. This will likely introduce generic competitors, impacting pricing and market share within the country.

Key Takeaways

  • Four notable drugs face patent expiry in Costa Rica during Q2 2026, including Lipitor, Cialis, Crestor, and Plavix.
  • Expiry dates range from April to June 2026, aligning with global patent timelines.
  • Generic entry post-expiry could influence local drug pricing and availability.
  • Patent term extensions and secondary patents may prolong exclusivity beyond the primary expiry date in certain cases.
  • Costa Rica’s adherence to TRIPS influences the patent duration and generic market entry.

FAQs

1. How accurate is the patent expiry information for Costa Rica?
It reflects publicly available patent data and known patent term extensions. Local regulatory delays or legal challenges can alter actual market entry timing.

2. Can generic versions be introduced immediately after patent expiry?
Not necessarily. Regulatory approval processes and any patent litigation or secondary patents can delay generic entry.

3. Are there secondary patents that could extend protection beyond the primary expiry?
Yes. Secondary patents or data exclusivity rights can extend protection, but their enforceability varies.

4. How does patent expiry influence drug affordability in Costa Rica?
It typically lowers prices due to increased generic competition, improving drug accessibility.

5. Are other drugs expected to lose exclusivity in 2026 outside of Q2?
Yes, though specific data for other periods requires detailed patent searches and legal analyses.

References

  1. Expiring Drug Patents database. (2023). Expiring-drug-patents-generic-entry. Retrieved from /p/expiring-drug-patents-generic-entry/index.php

More… ↓

⤷  Start Trial

When can AMYVID (florbetapir f-18) generic drug versions launch?

Generic name: florbetapir f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2026
Generic Entry Controlled by: Costa Rica Patent 10,329

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.

This drug has fifty-one patent family members in thirty-three countries. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.

When can FARYDAK (panobinostat lactate) generic drug versions launch?

Generic name: panobinostat lactate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 12, 2026
Generic Entry Controlled by: Costa Rica Patent 10,440

FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.

This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK

See drug price trends for FARYDAK.

The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.

When can INVOKAMET (canagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Costa Rica Patent 10,861

Drug Price Trends for INVOKAMET
INVOKAMET is a drug marketed by Janssen Pharms. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and seventy-one patent family members in forty-eight countries. There has been litigation on patents covering INVOKAMET

See drug price trends for INVOKAMET.

The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

When can INVOKAMET XR (canagliflozin; metformin hydrochloride) generic drug versions launch?

Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Costa Rica Patent 10,861

Drug Price Trends for INVOKAMET XR
INVOKAMET XR is a drug marketed by Janssen Pharms. There are three patents protecting this drug.

This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKAMET XR

See drug price trends for INVOKAMET XR.

The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

When can INVOKANA (canagliflozin) generic drug versions launch?

Generic name: canagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2026
Generic Entry Controlled by: Costa Rica Patent 10,861

Drug Price Trends for INVOKANA
INVOKANA is a drug marketed by Janssen Pharms. There are three patents protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market.

This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKANA

See drug price trends for INVOKANA.

The generic ingredient in INVOKANA is canagliflozin. There are twenty-one drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the canagliflozin profile page.

When can BEVYXXA (betrixaban) generic drug versions launch?

Generic name: betrixaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Costa Rica Patent 10,914
Patent Title: UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.

This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

When can KERENDIA (finerenone) generic drug versions launch?

Generic name: finerenone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 27, 2027
Generic Entry Controlled by: Costa Rica Patent 10,976

Drug Price Trends for KERENDIA
KERENDIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug.

This drug has ninety-seven patent family members in forty-nine countries. There has been litigation on patents covering KERENDIA

See drug price trends for KERENDIA.

The generic ingredient in KERENDIA is finerenone. One supplier is listed for this generic product. Additional details are available on the finerenone profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Costa Rica Patent 11,143

PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Costa Rica Patent 11,078

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

This drug has one hundred and thirty-five patent family members in forty-one countries.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.

Costa Rica Branded and Generic Drug Markets Assessment: Regulatory Opportunities and Challenges

Last updated: January 5, 2026

Summary

Costa Rica's pharmaceutical sector has experienced significant growth driven by its expanding healthcare system, aging population, and increasing demand for both branded and generic medicines. The country’s regulatory environment offers substantial opportunities for domestic and international companies but also presents unique challenges. This report provides a comprehensive analysis of the current market landscape, regulatory framework, and strategic considerations, including recent policy developments, market size, and competitive dynamics.

What Is the Market Overview of Costa Rica’s Pharmaceutical Sector?

Market Size and Growth

  • Pharmaceutical Market Value (2022): Estimated at USD 420 million, with a compounded annual growth rate (CAGR) of approximately 4.5% from 2018-2022.
  • Distribution: Branded drugs account for nearly 60%, with generics making up around 40% of prescription volumes.
  • Key Drivers: Growing healthcare expenditure, rising chronic disease prevalence, and increasing insurance coverage.

Key Market Segments

Segment Market Share (2022) Key Features
Branded pharmaceuticals 60% Predominantly imported, focus on innovative therapies
Generic pharmaceuticals 40% Cost-effective alternatives, growing local manufacturing
Over-the-counter (OTC) Significant portion Expanding consumer awareness, regulatory support

Competitive Landscape

Top Companies Market Share Type Country of Origin
Laboratorios
Lilly Costa Rica 15% Branded & Generics USA
Pfizer Costa Rica 12% Branded & Generics USA
Novartis Costa Rica 10% Branded Switzerland
Local manufacturers (e.g.,
Laboratorios de Costa Rica) 17% Generics & OTC Costa Rica

Note: The market is characterized by a mix of multinational corporations (MNCs) and local producers, with the latter gaining prominence in generics.

What Are the Regulatory Frameworks Governing Drug Approval and Market Entry?

Regulatory Authority

  • Cámara de Actividades Farmacéuticas (CAF) under the Ministry of Health (Ministerio de Salud) oversees pharmaceuticals.
  • Regulatory Mandates: Compliance with Costa Rican Pharmacopoeia, international standards (such as WHO), and registration protocols.

Drug Registration Process

Step Timeframe Documentation Required Notes
Application Submission 6-9 months Dossier with clinical, manufacturing, quality, and safety data Mirroring WHO prequalification and Costa Rican norms
Review & Evaluation 3-6 months Additional information requests Can extend if substantive issues arise
Approval & Registration Upon approval Certification, registration number Valid for 5 years, renewable annually

Recent Policy Developments

  • Regulatory Harmonization: Costa Rica aligns with Southern Common Market (MERCOSUR) standards for pharmaceuticals, facilitating regional market access.
  • Patent & Exclusivity Policies: The Costa Rican Patent Law (Law No. 7638, 2005) offers 20-year patent protections, affecting biosimilar and generic entry.
  • Price Control Regulations: The Ministry of Health issues price caps periodically, impacting profit margins and generic competitiveness.

What Opportunities Are Present in the Market?

Expansion of Generic Drug Market

  • Cost-Saving Drivers: Costa Rica’s universal healthcare system promotes generic substitution to contain costs.
  • Policy Incentives: Legislation encouraging generic prescribing and substitution, such as the 2014 “Law for Promotion of Generics.”

Developing Local Manufacturing

  • Investment Incentives: Costa Rican government offers tax incentives for pharmaceutical manufacturing (e.g., Free Trade Zone laws).
  • Supply Chain Benefits: Proximity to U.S. and Latin American markets, reducing logistics costs.

Opportunities in Niche and Innovative Therapies

  • Biologics & Biosimilars: Growing approval rates open avenues for biosimilar introductions.
  • Specialty Drugs: Increasing demand for oncology, rare diseases, and chronic illnesses.

Digital & Telepharmaceuticals

  • Recent regulatory updates facilitate telepharmacy and digital health solutions, opening new channels for drug distribution and patient engagement.

What Challenges Do Market Participants Face?

Regulatory Hurdles

  • Sluggish Approval Timelines: Lengthy registration processes may delay product launches.
  • Stringent Quality Requirements: High standards necessitate significant investment in compliance infrastructure.
  • Limited Local Expertise: Navigating complex regulations requires specialized legal and regulatory expertise.

Market Access Barriers

  • Price Controls: Arbitrary or frequent price caps can reduce margins, discouraging innovative and high-cost products.
  • Intellectual Property Considerations: Patent protections may delay generic or biosimilar market entry.
  • Market Fragmentation: Regional disparities in healthcare infrastructure lead to uneven demand.

Economic and Political Factors

  • Economic Stability: Fluctuations influence healthcare spending.
  • Policy Changes: Shifts in government priorities can alter pharmaceutical regulations and incentives.

Supply Chain & Distribution

  • Logistics Constraints: Limited cold chain infrastructure for biologics.
  • Import Dependence: Heavy reliance on imports for branded drugs leads to supply chain vulnerabilities.

How Does Costa Rica Compare to Regional Markets?

Aspect Costa Rica Panama Colombia Brazil
Market Size (USD Millions) 420 350 1,200 6,800
Regulatory Stringency Moderate Moderate High High
Generic Market Penetration (%) 40 35 50 40
Local Manufacturing Presence Emerging Limited Active Extensive
Price Control Impact (%) 10-15 12 20 25

Costa Rica maintains a balanced regulatory environment conducive to both innovation and generics, but regional competitors like Brazil exhibit more aggressive policies that influence market dynamics.

What Are the Strategic Implications for Market Entry?

Recommendations for Companies

Strategy Aspect Key Considerations
Regulatory Compliance Early engagement with authorities; investment in local legal expertise
Product Differentiation Focus on biosimilars, niche therapies, and value-added services
Local Partnerships Collaborations with Costa Rican manufacturers or healthcare providers
Pricing Strategy Alignment with government-controlled price caps and reimbursement policies

Timing and Market Penetration

  • Short-term: Focus on generics and OTC segments, leveraging existing local manufacturing.
  • Medium-term: Engage in biosimilar development and specialty drugs.
  • Long-term: Invest in innovative therapies, digital health, and regional expansion.

Conclusion and Key Takeaways

  • Costa Rica's pharmaceutical market offers attractive growth prospects driven by a universal healthcare system and increasing demand.
  • The regulatory environment, while comprehensive and aligned with regional standards, presents hurdles such as lengthy approval processes and price controls.
  • Opportunities are abundant in generics, biosimilars, and specialty therapies, particularly for firms capable of navigating local regulations and establishing strategic partnerships.
  • Challenges include regulatory delays, market fragmentation, and economic fluctuations, necessitating agile and well-informed market strategies.

FAQs

1. How accessible is the Costa Rican market for foreign pharmaceutical companies?
Foreign companies face a well-established but regulated landscape requiring compliance with local registration, quality standards, and price controls. Early engagement with regulators and local partners facilitates market entry.

2. What is the status of intellectual property rights in Costa Rica?
Costa Rica offers 20-year patent protections under Law No. 7638 (2005). However, patent term extensions and data exclusivity are limited, affecting biosimilar and generic competitiveness.

3. Are biosimilars gaining approval in Costa Rica?
Yes. Recent regulatory updates favor biosimilar approvals, aligning with WHO standards, providing opportunities for biologics and specialty drugs.

4. What role do price controls play in market strategy?
Price caps and reimbursement policies directly impact profit margins, prompting companies to focus on cost-effective generics and value-added niche products.

5. How is Costa Rica positioned for regional pharmaceutical expansion?
With good regional integration policies and access to Latin American markets, Costa Rica can serve as a manufacturing and distribution hub, especially for Andean markets and Central America.

References

  1. Ministerio de Salud Costa Rica. (2022). Regulation of pharmaceuticals.
  2. Costa Rican Patent Law (Law No. 7638). (2005).
  3. World Health Organization. (2021). Annual review of pharmaceutical regulations in Latin America.
  4. Costa Rica Investment Promotion Agency. (2022). Pharmaceutical manufacturing incentives.
  5. MarketResearch.com. (2022). Latin American pharmaceutical industry outlook.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links